Literature DB >> 6083454

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

D Klatzmann, E Champagne, S Chamaret, J Gruest, D Guetard, T Hercend, J C Gluckman, L Montagnier.   

Abstract

Many viruses, including retroviruses, are characterized by their specific cell tropism. Lymphadenopathy-associated virus (LAV) is a human lymphotropic retrovirus isolated from patients with acquired immune deficiency syndrome (AIDS) or related syndromes, that displays selective tropism for a subset of T lymphocytes defined by the expression of a surface glycoprotein of relative molecular mass 62,000 (62K) termed T4 (refs 6-8). This glycoprotein delineates a subset of T lymphocytes with mainly helper/inducer functions, while T lymphocytes of the reciprocal subset express a glycoprotein termed T8, have mainly cytotoxic/suppressor activities, and are unable to replicate LAV. Such a tropism may be controlled at the genomic level by regulatory sequences, as described for the human T-cell leukaemia viruses HTLV-I and -II (refs 2, 3). Alternatively or concomitantly, productive cell infection may be controlled at the membrane level, requiring the interaction of a specific cellular receptor with the virus envelope, as demonstrated recently for Epstein-Barr virus (EBV). Therefore, we have investigated whether the T4 molecule itself is related to the receptor for LAV. We report here that preincubation of T4+ lymphocytes with three individual monoclonal antibodies directed at the T4 glycoprotein blocked cell infection by LAV. This blocking effect was specific, as other monoclonal antibodies--such as antibody to histocompatibility locus antigen (HLA) class II or anti-T-cell natural killer (TNK) target--directed at other surface structures strongly expressed on activated cultured T4+ cells, did not prevent LAV infection. Direct virus neutralization by monoclonal antibodies was also ruled out. These results strongly support the view that a surface molecule directly involved in cellular functions acts as, or is related to, the receptor for a human retrovirus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6083454     DOI: 10.1038/312767a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  733 in total

1.  Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells.

Authors:  D Schenten; L Marcon; G B Karlsson; C Parolin; T Kodama; N Gerard; J Sodroski
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.

Authors:  X Yang; L Florin; M Farzan; P Kolchinsky; P D Kwong; J Sodroski; R Wyatt
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.

Authors:  P D Kwong; R Wyatt; Q J Sattentau; J Sodroski; W A Hendrickson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 5.  Current concepts in human immunodeficiency virus infection and AIDS.

Authors:  S A Schwartz; M P Nair
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

Review 6.  Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.

Authors:  J Overbaugh; A D Miller; M V Eiden
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

7.  Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.

Authors:  N Genois; B Barbeau; M Olivier; M J Tremblay
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

8.  Cystein 402 of HIV gp 120 is essential for CD4-binding and resistance of gp 120 to intracellular degradation.

Authors:  A Hemming; A Bolmstedt; P Flodby; L Lundberg; M Gidlund; H Wigzell; S Olofsson
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

Review 9.  Immunological tolerance as a barrier to protective HIV humoral immunity.

Authors:  Kristin Ms Schroeder; Amanda Agazio; Raul M Torres
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

10.  Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.

Authors:  L O Arthur; J W Bess; D J Waters; S W Pyle; J C Kelliher; P L Nara; K Krohn; W G Robey; A J Langlois; R C Gallo
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.